Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Docetaxel effectively mobilizes peripheral blood CD34+ cells.

H M Prince1, G C Toner, J F Seymour

  • 1Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.

Bone Marrow Transplantation
|October 6, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

Frontiers in oncology·2025
Same author

Impacts of a Clinical Quality Registry on Lung Cancer Quality Measures: A Retrospective Observational Study of the Victorian Lung Cancer Registry.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Characterizing and Targeting of BCL-2 Family Members in Nasopharyngeal Carcinoma.

Head & neck·2024
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Surgical Management of Ebstein Anomaly: The Australia and New Zealand Experience.

World journal for pediatric & congenital heart surgery·2024
Same author

Anomalous Right Coronary Artery Originating From the Pulmonary Artery (ARCAPA): A Rare Presentation in the Fifth Decade.

World journal for pediatric & congenital heart surgery·2022

Docetaxel combined with G-CSF effectively mobilizes peripheral blood progenitor cells (PBPCs) in breast cancer patients. This regimen achieves target CD34+ cell yields for high-dose therapy, with apheresis best initiated around day 8 post-treatment.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Mobilization of peripheral blood progenitor cells (PBPCs) is crucial for high-dose therapy (HDT) and autologous stem cell transplantation.
  • Docetaxel is a chemotherapy agent used in breast cancer treatment, and G-CSF (granulocyte-colony stimulating factor) is often used to stimulate blood cell production.

Purpose of the Study:

  • To prospectively evaluate the efficiency of docetaxel plus G-CSF in mobilizing PBPCs for breast cancer patients undergoing HDT.
  • To determine the optimal timing for apheresis collection after docetaxel administration to achieve target CD34+ cell yields.

Main Methods:

  • Prospective evaluation of 26 breast cancer patients receiving docetaxel (100 mg/m2) followed by G-CSF (10 microg/kg daily).
  • Monitoring of peripheral blood CD34+ cell counts to determine peak mobilization days and collection efficiency.

Related Experiment Videos

  • Analysis of apheresis collection data, including total CD34+ cell yield and time to hematological recovery post-transplantation.

    • Main Results:

    • The combination of docetaxel and G-CSF effectively mobilized PBPCs, with peak CD34+ cell counts observed on days 8 and 9.
    • A median total CD34+ cell yield of 9.7 x 10(6)/kg was achieved, meeting the minimum target of >4.5 x 10(6)/kg in 22 out of 26 patients.
    • Hematological recovery, including absolute neutrophil count and platelet levels, was observed within acceptable timeframes following HDT and PBPC transplantation.

    Conclusions:

    • Docetaxel with G-CSF is an effective regimen for mobilizing PBPCs in breast cancer patients, enabling successful subsequent high-dose therapy and transplantation.
    • Apheresis collection should be initiated approximately 8 days after docetaxel administration to maximize CD34+ cell yield.
    • This mobilization strategy supports repetitive high-dose therapy cycles, demonstrating its clinical utility in managing breast cancer.